Phibro Animal Health (PAHC) is back on investors’ radar after reporting earnings and revenue that surpassed expectations, supported by stronger vaccine sales and the integration of Zoetis’ MFA business, which is reinforcing interest in its animal health portfolio.

The share price has reacted strongly to this run of positive updates, with a 30 day share price return of 15.9% and a 90 day share price return of 44.7%. This has contributed to a very large 1 year total shareholder return and suggests powerful momentum rather than a short term bounce.

If this kind of move catches your eye, it could be a good time to see what else is working in the market and check out 20 top founder-led companies

With the shares up sharply and trading above the average analyst price target of US$48.50, the market clearly likes Phibro’s story. However, does the large intrinsic discount hint at further upside, or is future growth already priced in?

Most Popular Narrative: 14.5% Overvalued

Phibro's most followed narrative places fair value at $48.50, compared with the last close at $55.52, so the current price sits above that reference point.

The company's strong recent growth is heavily dependent on the integration of the acquired Zoetis Medicated Feed Additive business and related cost synergies, which are non-repeatable. Forward guidance suggests legacy product growth will slow to flat or low single digits, implying the current trajectory of accelerating revenue and EBITDA growth is unsustainable and likely to normalize, impacting revenue and earnings growth expectations.

Curious how a business with moderate forecast revenue growth, higher margins and a lower future P/E assumption still lands at that fair value estimate? The narrative leans heavily on a detailed revenue bridge, margin progression and discount rate choice that you might want to test against your own expectations.

Result: Fair Value of $48.50 (OVERVALUED)

However, strong global protein demand, along with further benefits from the Zoetis MFA acquisition, could keep revenue and margins firmer than this cautious narrative assumes.

Another View: Cash Flows Tell a Very Different Story

While the most popular narrative sees Phibro Animal Health as 14.5% overvalued at $55.52 versus a $48.50 fair value, the SWS DCF model points in the opposite direction. On that approach, the shares trade at a 53.4% discount to an estimated future cash flow value of $119.16.

If earnings based views lean cautious yet long term cash flows suggest a large gap, the real question for you is which set of assumptions feels more realistic for the next phase of this business.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Phibro Animal Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of optimism and caution in this article highlights how divided the outlook can be, so move quickly to review the numbers yourself and weigh up the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If this kind of valuation debate gets you thinking, do not stop at one stock. Broaden your watchlist and let the data work harder for you.

• Zero in on quality at a discount by scanning 58 high quality undervalued stocks that pair solid fundamentals with what may be appealing pricing.
• Strengthen your income stream by reviewing 13 dividend fortresses that combine higher yields with an emphasis on resilience.
• Prioritize resilience and sleep easier at night by checking 68 resilient stocks with low risk scores that score well on financial and risk filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.